Stay updated with breaking news from Nasdaq Eldn. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Tuesday, Zacks.com reports. According to Zacks, “Eledon Pharmaceuticals Inc. is a clinical stage biotechnology company. It develop treatments for an organ or cell-based transplant, and for people with autoimmune […]
Analysts at Cantor Fitzgerald initiated coverage on shares of Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) in a research report issued on Friday, FinViz reports. The firm set an “overweight” rating and a $15.00 price target on the stock. ELDN has been the topic of several other reports. HC Wainwright reaffirmed a “buy” rating and issued […]
Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating)‘s stock had its “overweight” rating reissued by stock analysts at Cantor Fitzgerald in a note issued to investors on Tuesday, Zacks.com reports. Several other analysts have also issued reports on the company. Zacks Investment Research upgraded Eledon Pharmaceuticals from a “sell” rating to a “hold” rating in a research […]
Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) announced its quarterly earnings results on Thursday. The company reported ($0.59) EPS for the quarter, topping the consensus estimate of ($0.75) by $0.16, MarketWatch Earnings reports. Shares of NASDAQ ELDN traded up $0.15 during mid-day trading on Friday, hitting $3.90. 63,630 shares of the company’s stock traded hands, compared […]
Equities analysts expect Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Rating) to post earnings of ($0.74) per share for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for Eledon Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.74) and the lowest estimate coming in at ($0.92). The business is expected to […]